Trinity moves into autoimmune testing with $33m acquisition
This article was originally published in Clinica
Executive Summary
Irish diagnostics specialist Trinity Biotech has continued to expand its offering, this time diversifying into the autoimmune testing field with the acquisition of Immco Diagnostics for $32.75m. However, unlike its other more recent purchases, Sweden’s Fiomi Diagnostics (www.clinica.co.uk, 2 March 2012) and Phoenix Biotech in 2011, Trinity’s latest deal is not within point-of-care (POC) testing but sits in the more traditional lab diagnostics and services space. Trinity believes that there are synergies between Immco’s offering and its existing infectious disease testing portfolio.